Business Wire

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and ...
Nasdaq

Solid Biosciences Reports Promising Initial Data from Phase 1/2 INSPIRE DUCHENNE Trial for SGT-003 in Duchenne Muscular Dystrophy

Solid Biosciences has reported promising initial findings from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy aimed at treating Duchenne muscular dystrophy. Data from the first three ...
Nasdaq

Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected ...

– Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subset of patients, tumor shrinkage in injected and ...